| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 华纳药厂成立于2001年，于2021年在上交所科创板上市；是一家拥有多个研发中心、可对接全球创新资源，覆盖中药、化药、生物大分子药物产业链，立足中国、布局全球的创新驱动型药品生产企业。 公司专一、专注于主营业务拓展；通过产品的集群开发与平台技术的创新共享，培植起原料制剂一体化的优势化药产业链，形成了国内一流、具有国际市场竞争优势的高端化药产业化平台；并以濒危动物药材替代品、植提原料等特色中药为契入点，持续打造特色创新中药产业化平台。实现了研发、生产、销售的协调发展，和营收、利润的快速、稳定增长。 秉持“科技服务健康”的企业宗旨，运用科学技术成果维护患者生命健康、提高患者生命质量是公司持续创新的原动力；未来公司将遵循“潜心制药、诚信待人”的经营理念，致力于把华纳药厂打造“成为一个值得信赖的健康产品供应商”。 | ||||||||||||||||||||||||
| Main Business | 化学原料药、化学药制剂和中药制剂的研发、生产与销售。 | ||||||||||||||||||||||||
| Legal Representative | 黄本东 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 窦琳 | ||||||||||||||||||||||||
| Solicitors | 北京市康达律师事务所 | ||||||||||||||||||||||||
| Auditors | 天健会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0731-85910599 | ||||||||||||||||||||||||
| Fax No | 0731-85910568 | ||||||||||||||||||||||||
| Website | www.warrant.com.cn | ||||||||||||||||||||||||
| hnddm@warrant.com.cn;lmc@warrant.com.cn | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 13/07/2021 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 2.250 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.900 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 18.374 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 4.002B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |